Short answer
Moderna (MRNA) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation). Interest margins reduced 0.75 percentage points, to 4.75% SOFR-based and 3.75% base-rate loans.
Moderna 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Interest margins reduced 0.75 percentage points, to 4.75% SOFR-based and 3.75% base-rate loans
- Term-loan maturity extended one year, from November 24, 2030 to November 24, 2031
- Delayed-draw availability extended to November 24, 2029 for $400 million and $500 million commitments
- Lower borrowing costs and longer access improve Moderna’s financing flexibility, while existing guarantees and collateral remain in place
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 points to Item 1.01 for the terms of Moderna’s new direct financial obligation
- Investors should review Item 1.01 for obligation amount, maturity, interest rate, and purpose
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Moderna 8-K filings
Get the next MRNA 8-K as it lands
Follow MRNA for push alerts, or ask the research agent what this filing means.